Evidence map›Paper›PMID 32695909›Full record

ArticleHeliyon2020

Novel 3,4-diarylpyrazole as prospective anti-cancerous agents.

Vivek Pandey, Garima Tripathi, Dhruv Kumar, Abhijeet Kumar, Pawan K Dubey

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Journal of biomolecular structure & dynamics · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Vivek PandeyCentre for Genetic Disorder, Banaras Hindu University, Varanasi, U.P., India.
Garima TripathiDepartment of Chemistry, T. N. B. College, TMBU, Bhagalpur, Bihar, India.
Dhruv KumarAmity Institute of Molecular Medicine & Stem Cell Research, Amity University Uttar Pradesh, Noida, India.
Abhijeet KumarDepartment of Chemistry, School of Physical Sciences, Mahatma Gandhi Central University, Bihar, India.
Pawan K DubeyCentre for Genetic Disorder, Banaras Hindu University, Varanasi, U.P., India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer is a leading cause of death globally. Despite therapeutic advancements the mortality rate of cancer is continuously increasing. Thus, it is important to identify and design potential therapeutic agents which can specifically bind with most common targets of cancer and inhibit tumor progression. The present work discloses the potential therapeutic application of the novel 3,4-diaryl 1

Indexed as

ApoptosisBioinformaticsBiological sciencesCell biologyChemistryMDA-MB-231Molecular dockingOrganic chemistryPharmaceutical chemistryPyrazoleReactive oxygen species

Identifiers

PMID32695909
PMCPMC7364028

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.